Kriya Therapeutics completed the acquisition of Redpin Therapeutics.

Kriya Therapeutics, a fully integrated gene therapy company, completed the acquisition of Redpin Therapeutics, a privately held biotechnology company. Financial terms were not disclosed. “Redpin has a built a breakthrough, validated chemogenetics approach that could have significant potential in the targeted treatment of neurological disorders. Kriya Therapeutics is the perfect company to take this leading ion channel-based platform forward and deliver an effective treatment option for patients. We look forward to working with the Kriya team to progress these unique targeted therapies to patients in need as rapidly as possible,” Elma Hawkins, Redpin Therapeutics President, Chief Executive Officer and Co-founder.